NDT Pharmaceuticals Inc. (NDTP)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -25.17 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | -1240.00 USD | 35.75% |
| 2016 | -1930.00 USD | 97.79% |
| 2015 | -87.33 Thousand USD | 66.5% |
| 2014 | -260.67 Thousand USD | 0.0% |
| 2010 | -246.24 Thousand USD | 0.0% |
| 2007 | -1.06 Million USD | -1952.76% |
| 2006 | -51.76 Thousand USD | -796.6% |
| 2005 | -5773.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1520.00 USD | 44.12% |
| 2024 Q3 | -2200.00 USD | 78.37% |
| 2024 Q2 | -10.17 Thousand USD | -569.08% |
| 2023 Q4 | -2720.00 USD | -32.04% |
| 2023 FY | -25.17 Thousand USD | 0.0% |
| 2023 Q1 | -11.26 Thousand USD | 0.0% |
| 2023 Q2 | -9130.00 USD | 18.92% |
| 2023 Q3 | -2060.00 USD | 77.44% |
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | -1240.00 USD | 35.75% |
| 2016 FY | -1930.00 USD | 97.79% |
| 2015 FY | -87.33 Thousand USD | 66.5% |
| 2014 FY | -260.67 Thousand USD | 0.0% |
| 2011 Q1 | -19.9 Thousand USD | -13.0% |
| 2011 Q2 | -9490.00 USD | 52.31% |
| 2010 Q1 | -12.95 Thousand USD | 0.0% |
| 2010 FY | -246.24 Thousand USD | 0.0% |
| 2010 Q4 | -17.61 Thousand USD | -69.82% |
| 2010 Q3 | -10.37 Thousand USD | 94.95% |
| 2010 Q2 | -205.31 Thousand USD | -1485.41% |
| 2008 Q1 | -20.74 Thousand USD | 97.97% |
| 2008 Q2 | -33.24 Thousand USD | -60.25% |
| 2007 Q3 | -18.14 Thousand USD | -53.75% |
| 2007 FY | -1.06 Million USD | -1952.76% |
| 2007 Q4 | -1.02 Million USD | -5535.73% |
| 2007 Q1 | -10.15 Thousand USD | 49.36% |
| 2007 Q2 | -11.8 Thousand USD | -16.23% |
| 2006 Q4 | -20.04 Thousand USD | -159.73% |
| 2006 Q2 | -3761.00 USD | 81.39% |
| 2006 Q1 | -20.2 Thousand USD | 0.0% |
| 2006 Q3 | -7718.00 USD | -105.21% |
| 2006 FY | -51.76 Thousand USD | -796.6% |
| 2005 FY | -5773.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | 82.137% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 96.336% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 85.324% |
| CytoDyn Inc. | -18.05 Million USD | 99.861% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.957% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -3382.243% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 98.614% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 99.501% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 15.966% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 86.131% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.741% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.955% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.967% |
| Resverlogix Corp. | -12.74 Million USD | 99.803% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 93.539% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.258% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 98.975% |
| Mesoblast Limited | -84.14 Million USD | 99.97% |
| GB Sciences, Inc. | -1.42 Million USD | 98.228% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 96.336% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.859% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 99.261% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 99.621% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 99.206% |
| ContraFect Corporation | -56.88 Million USD | 99.956% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 99.085% |
| BioStem Technologies, Inc. | -7.77 Million USD | 99.676% |
| LadRx Corporation | -3.82 Million USD | 99.342% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.841% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 97.751% |
| CSL Limited | 3.7 Billion USD | 100.001% |
| Biomind Labs Inc. | -1 Million USD | 97.507% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 97.298% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.031% |
| Nascent Biotech, Inc. | -2.22 Million USD | 98.871% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.965% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.512% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.711% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 98.361% |
| Marizyme, Inc. | -34.08 Million USD | 99.926% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 99.699% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 95.543% |
| Zenith Capital Corp. | -8.94 Million USD | 99.719% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 99.117% |
| Halberd Corporation | -75.05 Thousand USD | 66.462% |
| Genus plc | 6.4 Million USD | 100.393% |
| Pharming Group N.V. | -4.87 Million USD | 99.484% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 98.733% |
| IMV Inc. | -38.67 Million USD | 99.935% |
| Affymax, Inc. | -15.04 Million USD | 99.833% |
| SYBLEU INC | -149.18 Thousand USD | 83.128% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 97.589% |
| Enzolytics Inc. | -2.14 Million USD | 98.829% |
| argenx SE | -425.04 Million USD | 99.994% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.376% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 98.205% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 98.115% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.328% |
| Cell Source, Inc. | -4.32 Million USD | 99.418% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 94.789% |
| Q BioMed Inc. | -3.44 Million USD | 99.27% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 99.406% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 97.996% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 99.042% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 99.447% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.954% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 99.132% |
| Rebus Holdings, Inc. | -664 Thousand USD | 96.209% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 97.442% |
| Skye Bioscience, Inc. | -13.67 Million USD | 99.816% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 98.65% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 98.744% |
| ONE Bio Corp. | 13.68 Million USD | 100.184% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 98.698% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 97.762% |
| Agentix Corp. | -1.37 Million USD | 98.165% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 99.138% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 98.406% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -44.481% |
| Kadimastem Ltd | -3.04 Million USD | 99.172% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 90.383% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 93.942% |
| NovAccess Global Inc. | -2.46 Million USD | 98.98% |
| Itoco Inc. | -919.14 Thousand USD | 97.262% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 88.563% |
| Qrons Inc. | -643.67 Thousand USD | 96.09% |
| Mobile Lads Corp. | -554.55 Thousand USD | 95.461% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.994% |
| International Stem Cell Corporation | -663 Thousand USD | 96.204% |
| Bioxytran, Inc. | -3.82 Million USD | 99.341% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 52.185% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -23.746% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.931% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 98.444% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 96.579% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 99.191% |
| Neutra Corp. | -229.48 Thousand USD | 89.032% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.856% |
| PureTech Health plc | -146.19 Million USD | 99.983% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.883% |
| IXICO plc | -1.43 Million USD | 98.248% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 99.735% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.979% |
| CSL Limited | 3.81 Billion USD | 100.001% |
| Cellectis S.A. | -108.85 Million USD | 99.977% |